Literature DB >> 29697549

Endoscopic Electrocautery Incisional Therapy as a Treatment for Refractory Benign Pediatric Esophageal Strictures.

Michael A Manfredi1,2, Susannah J Clark3,2, Shawn Medford1, Steven J Staffa4, Peter D Ngo1,2, Thomas E Hamilton3,2, C Jason Smithers3,2, Russell W Jennings3,2.   

Abstract

BACKGROUND AND AIM: Refractory esophageal strictures are rare conditions in pediatrics, and are often due to anastomotic, congenital, or caustic strictures. Traditional treatment options include serial dilation and surgical stricture resection; endoscopic intralesional steroid injections, mitomycin C, and externally removable stents combined with dilation have had variable success rates. Although not as widely used, endoscopic electrocautery incisional therapy (EIT) has been reported as an alternative treatment for refractory strictures in a small number of adult series. The aim of the study was to evaluate the safety and efficacy of EIT in a pediatric population with refractory esophageal strictures.
METHODS: A retrospective chart review was conducted on all patients who underwent EIT for esophageal strictures (May 2011-September 2017) at our tertiary-care referral center. A total of 57 patients underwent EIT. Procedural success was defined as no stricture resection, appropriate diameter for age, and fewer than 7 dilations within 24 months of first EIT session. This corresponded to the 90th percentile of the observed number of dilations in the data. All patients included in the study had at least 2-year follow-up.
RESULTS: A total of 133 EIT sessions on 58 distinct anastomotic strictures were performed on 57 patients (24 girls). The youngest patient to have EIT was 3 months old and 4.8 kg. There were 36 strictures that met the criteria for refractory stricture and 22 non-refractory (NR) strictures. The median number of dilations before EIT therapy was 8 (interquartile range [IQR]: 6-10) in the refractory group and 3 (IQR: 0-3) in the NR group. In the refractory group, 61% of the patients met the criteria for treatment success. The median number of dilations within 2 years of EIT in the refractory group was 2 (IQR: 0-4). In the NR group, 100% of the patients met criteria for success. The median number of dilations within 2 years of EIT in the NR was 1 (IQR: 0-2). The overall adverse event rate was 5.3% (7/133), with 3 major (2.3%) and 4 minor events (3%).
CONCLUSIONS: EIT shows promise as an adjunct treatment option for pediatric refractory esophageal strictures and may be considered before surgical resection even in severe cases. The complication rate, albeit low, is significant, and EIT should only be considered by experienced endoscopists in close consultation with surgery. Further prospective longitudinal studies are needed to validate this treatment.

Entities:  

Mesh:

Year:  2018        PMID: 29697549     DOI: 10.1097/MPG.0000000000002008

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  4 in total

1.  Utility of functional lumen imaging probe in esophageal measurements and dilations: a single pediatric center experience.

Authors:  Kenneth Ng; Douglas Mogul; John Hollier; Mouen A Khashab
Journal:  Surg Endosc       Date:  2019-06-11       Impact factor: 4.584

Review 2.  Endoscopic Management of Luminal Strictures: Beyond Dilation.

Authors:  Nader D Daoud; Hassan Ghoz; Obaie Mzaik; Himesh B Zaver; Micah McKinney; Bhaumik Brahmbhatt; Timothy Woodward
Journal:  Dig Dis Sci       Date:  2022-02-25       Impact factor: 3.199

3.  Endoscopic ultrasonography guided cutting scar of esophageal stricture after endoscopic injection sclerotherapy.

Authors:  Fulong Zhang; Jing Xu; Yuandong Zhu; Yan Shi; Bo Wu; Hai Wang; Chaojun Huang
Journal:  BMC Gastroenterol       Date:  2022-07-15       Impact factor: 2.847

4.  Therapeutic Upper Gastrointestinal Endoscopy in Pediatric Gastroenterology.

Authors:  Dominique Schluckebier; Nadeem Ahmad Afzal; Mike Thomson
Journal:  Front Pediatr       Date:  2022-02-25       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.